A Study to Learn How Different Forms of Study Medicine CTB-AVP Are Taken up Into the Blood and How It Is Taken up Into The Blood When Taken on An Empty Stomach or Taken With a Meal in Healthy Adults
This research study is about understanding how a new medication called CTB-AVP works in the body. Specifically, it's looking at how different forms of this medicine get absorbed into the bloodstream. Researchers also want to find out if taking the medicine with food or on an empty stomach changes how well it's absorbed. This information is important because CTB-AVP is being developed to treat serious infections of the bladder and kidneys, known as complicated urinary tract infections, including a type called pyelonephritis. By studying healthy adults first, scientists can learn important details about the medicine's behaviour before it's tested in people who are unwell. This helps ensure future trials are as safe and effective as possible.
At a glance
What is this study about?
This study is a very early stage of research, sometimes called a Phase I study. Doctors and scientists are trying to understand exactly how a new medicine, called CTB-AVP, behaves once it’s in the human body. They want to see how much of the medicine gets into the bloodstream and how quickly this happens. This information is really important because it helps them work out the best way to give the medicine in the future.
A key part of this study is looking at different versions (forms) of CTB-AVP and whether taking the medicine with a meal or on an empty stomach makes a difference. Sometimes, food can change how well a medicine is absorbed, making it work better or worse. By finding this out early, researchers can give clear instructions later on about how patients should take the medicine.
This new medicine is being developed to treat serious types of urinary tract infections (UTIs). These infections can affect the bladder and sometimes spread to the kidneys, which is called pyelonephritis. UTIs can be very painful and, if they become complicated, can be quite serious. Understanding CTB-AVP's behaviour in healthy people now will help ensure that if it goes on to treat patients with these infections, it will be given in the most effective way.
Key takeaways
- This study helps understand how a new medicine for serious UTIs works in the body.
- It's an early-stage study involving healthy adults.
- Researchers want to see if food affects medicine absorption.
- Your participation could help develop future treatments.
- You'll be closely monitored by a medical team.
Who may be eligible?
To join this study, people typically need to be healthy adults, usually 18 years old or older. The study is open to both men and women.
Being 'healthy' means that you don't have any major ongoing medical conditions that could interfere with how the study medicine works or make your participation unsafe. This usually involves a doctor checking your general health and medical history.
The research team will have a specific list of health checks and requirements to make sure the study is right and safe for you. They will go through these details carefully with you if you are interested in taking part.
- Are you 18 years old or older?
- Are you generally healthy?
- Are you able to attend several clinic visits?
- Are you comfortable with blood tests?
- Are you prepared to follow specific instructions on taking medicine with or without food?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part, you would receive the study medicine, CTB-AVP. You would likely visit a clinic or research unit multiple times. During these visits, the research team would monitor your health and take blood samples at specific times to measure how the medicine is absorbed and leaves your body. You might also be asked to take the medicine in different ways, such as on an empty stomach or after a meal, so researchers can compare the effects. The total duration of your involvement could vary, but Phase I studies often involve a series of visits over a few weeks or months, with follow-up checks.
Potential risks and benefits
Locations (1)
- —Belgium
Common questions
What is a 'Phase I' study?
It's an early stage of human testing where researchers mainly focus on how safe a new medicine is and how it behaves in the body, often involving healthy volunteers.
Why are healthy people in a study for an infection medicine?
Studying healthy people helps researchers understand the basic movements of the medicine in the body without other illnesses complicating the results. This makes future testing safer and more effective for patients.
What is a 'complicated urinary tract infection'?
This is a serious bladder or kidney infection that might need more specific treatment, sometimes because of other health problems or if it involves the kidneys (pyelonephritis).
Will I know if I'm getting the 'different forms' of the medicine?
The research staff will explain exactly what you will be given and when, including any variations in the medicine or instructions about food.
Do I have to pay to join the study?
No, you do not have to pay to participate in a clinical trial. Any study-related costs are covered by the research team.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.